Psoriasis is a common cutaneous disease with multifactorial etiology including genetic and non-genetic factors, such as drugs, smoking, drinking, diet, infection and mental stress. Now, the role of the interaction between environmental factors and genetics are considered to be a main factor in the pathogenesis of psoriasis. However, it is a challenge to explore the mechanisms how the environmental factors break the body balance to affect the onset and development of psoriasis. In this article, we review the pathogenesis of psoriasis and summarize numerous clinical data to reveal the association between environmental factors and psoriasis. In addition, we focus on the mechanisms of environmental risk factors impact on psoriasis and provide a series of potential treatments against environmental risk factors.
INTRODUCTION
Psoriasis is a chronic and recurrent inflammatory skin disease which is characterized by hyperproliferative keratinocytes and infiltrating immune cells, including T cells, dendritic cells, macrophages and neutrophils. The main clinical features of psoriasis are a thick epidermis that expresses keratin 16 (K16) in cells above the basal layer and consistent T-lymphocyte (positive by CD3 staining) infiltration into both the epidermis and dermis of lesions. The prevalence in adults ranges 0.51-11.43%, and in children 0-1.37% depending on age, geographic location and genetic background. [1] [2] [3] Initially, psoriasis was just considered a disease with hyperproliferation and abnormal differentiation of keratinocytes, while current researches confirm that psoriasis is an autoimmune skin disease characterized by T-cell-mediated responses. The imbalance among CD4 + T-cell subsets contributes to hyperkeratosis and parakeratosis. 4, 5 Various T-cell subsets, such as T-helper (Th)1, Th2, Th17 and regulatory T cells (Treg), are involved in the immunopathogenesis and chronic inflammation response of psoriasis. The fact that Th1 and Th17 cells increase while Th2 and Treg decrease has been found in patients with psoriasis. So, blockade of pathogenic T-cell activation contributes to the improvement of both clinical and histopathological disease condition, including abnormal K16 expression and excessive T-cell infiltration. Currently, psoriasis is believed to be triggered by the combination of genetic, epigenetic and environmental influences, and its genetic diversity and epigenetic modifications can be influenced by environmental factors. [6] [7] [8] T cells have been believed to be a key mediator in psoriasis. Environmental risk factors trigger the immune response of the body, where naive T cells are activated by antigen-presenting cells (APC) in the epidermis, especially Langerhans cells. APC can also release cytokines such as interleukin (IL)-12 and IL-23, which promote naive T cells to differentiate into Th1 and Th17 cells. 9 Then, the activated T cells migrate from lymph nodes to skin, where they are stimulated to produce plenty of cytokines. Therefore, these cytokines interact with the resident epidermal and dermal cells and then cause changes, including keratinocyte proliferation and epidermal thickness. All the changes involved in the two main pathways around T cells include: IL-2/Th1/interferon (IFN)-c and IL-23/Th17/IL-17. In the first pathway, IFN-c produced by activated Th1 cells induces the expression of co-stimulatory molecules on dendritic cells and intercellular adhesion molecule (ICAM)-1 on keratinocytes, stimulates tumor necrosis factor (TNF)-a release from macrophages, thus inhibiting keratinocyte apoptosis. 10 In the second pathway, Th17 cells release the main effector cytokines IL-17 and IL-22. IL-17 can influence the expression of cytokines such as TNF-a and ICAM-1, increase keratinocyte expression of chemokines and reduce expression of cell adhesion molecules. 11 IL-22 also promotes the proliferation of keratinocytes. 12 Both of them result in the disruption of the skin barrier ( Fig. 1) . Unfortunately, there is no cure for psoriasis at present, and most of the current treatments just manage the symptoms by drugs while omitting the importance of avoiding risk factors, such as excess ultraviolet (UV) exposure, specific drugs, infections, smoking, alcohol abusing and stress, and the critical role of them on psoriasis are summarized in Table 1 .
PATHOGENESIS OF PSORIASIS Genetic polymorphism and epigenetic modification in psoriasis
The pathogenesis of psoriasis mainly relates to the combined effect of multiple gene susceptibility loci, the disordered immune system together with pervasive environmental risk factors. Genome-wide association studies (GWAS) have been applied successfully in psoriasis to explore the genetic architecture. Large amounts of data indicate psoriasis-susceptibility loci or candidate genes (showed in Table 2 ) among different populations, such as PSORS1 that could account for 35-40% in psoriasis in heritability. [13] [14] [15] In brief, the gene variants associated with psoriasis can generally be divided into two categories: immune-specific and skin-specific genes. 16 Among them, it is worth mentioning that mutations of caspase recruitment domain-containing protein 14 (CARD14) and IL36RN genes have been recognized as responsible genetic factors of generalized pustular psoriasis. 17, 18 The CARD14 gene encodes a protein that promotes the activation of nuclear factor (NF)-jB and upregulates the expression of pro-inflammatory pathway genes. 19 IL36RN encodes the IL-36 receptor antagonist (IL36Ra) which counteracts the inflammatory effect of IL-36 cytokines (IL-36a, IL-36b and IL-36c) by binding their receptor (IL-1RL2) and prevents the downstream activation of NF-jB signaling. 20 Recent studies identified more than dozens of gene locus mutations of CARD14 and IL36RN, which differed depending on geography and race. Now, psoriasis is commonly described as a T-cell-mediated autoimmune disease, in which IFN-c and TNF-a act as key pro-inflammatory players influenced by environmental factors and susceptibility genes. Several biologics targeting cytokines and T cells have been approved by the US Food and Drug Administration (FDA) applied in clinics to treat psoriasis. Psoriasis is a multigene disorder whose manifestation and severity are likely to depend on the patient's genetic background. 21, 22 The incidence of psoriasis increased significantly (P < 0.05) in the patients' relatives and the concordance rate was much higher between monozygotic twins (65-72%) than dizygotic twins (15-30%), which indicated that genetic linkage played the key role in psoriasis. 2, [23] [24] [25] Family lineage studies suggest that psoriasis has two different genetic subpopulations, one with multifactorial Figure 1 . Psoriasis pathogenesis. Psoriasis is believed to be triggered by a combination of genetic, disordered immune system and environmental influences, and its genetics and immune system can be affected by environmental factors. Naive T cells are activated by antigen-presenting cells (APC) in the epidermis, which promote naive T cells to differentiate into T-helper (Th)1 and Th17, so that Th1 and Th17 cells increase while Th2 and regulatory T cells (Treg) decrease. Then, the activated T cells migrate from lymph nodes to skin, where they are stimulated to produce plenty of cytokines. So these cytokines interact with the resident epidermal and dermal cells and then cause changes, including keratinocyte proliferation and epidermal thickness. DC, dendritic cells; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor; UV, ultraviolet. 34 had verified that environmental elements (including mental stress, infection, trauma, damp, drugs smoking and drinking) were all the risk factors in the course of occurrence, aggravation and recurrence of psoriasis and found that human leukocyte antigen (HLA)-A26 had significant positive correlation with psoriasis of no environmental exposure (P < 0.0001). In their research, they illustrated that environmental factors had significant interaction with HLA-A26. Jin et al. discovered the joint effect of HLA-Cw6 and smoking, a wonderful explanation to identify the susceptibly variant related to psoriasis. The risk of psoriasis is 11-fold less for non-smokers without the HLACw6 gene in comparison with smokers carrying the HLA-Cw6 gene in the Chinese Han population. 35 GWAS have verified amounts of genes correlated with environmental risks of psoriasis. As we all know, obesity is a common risk factor for psoriasis, and the roles of genetic factors may be modified by obesity in psoriasis development. [35] [36] [37] Li et al. 38 demonstrated the epigenetic modifying action of obesity in the relevance of psoriasis and genetic variants, and they even affirmed the increased risk of psoriasis related to the single nucleotide polymorphism in IL-12B. Although little is known about the mechanism of gene-environment interactions in psoriasis, we have the opportunity to evaluate gene-environment interactions in cohort studies because plenty of published GWAS applied to psoriasis since 2007.
Interaction between environmental factors and epigenetics in psoriasis
Epidemiological studies have showed that environmental risk factors may result in the susceptibility and severity of psoriasis among isogenic lines by epigenetic changes. 39 Recently, epigenetic modification changes including DNA methylation, histone modification and non-coding RNA have been found to be involved in many diseases, such as psoriasis. These epigenetic changes can often been seen in the pathogenesis of psoriasis. Secreted frizzled-related protein (SFRP)4, a negative regulator of the Wnt signaling pathway, can directly inhibit pathological keratinocyte proliferation induced by pro-inflammatory cytokines, and the high methylation level of the promoter has led to epigenetic downregulation of SFRP4 in inflamed skin of psoriatic patients and imiquimod mouse models, which contributed to the hyperplasia of epidermis in psoriasis. 40 In a study directed by Zhou et al., 41 the researchers found nine instances of skin-specific DNA methylation of differentially methylated sites associated with psoriasis by a three-stage epigenome-wide association study, which were not obviously influenced by genetic variations. Among them, the expression levels of CYP2S1, ECE1, EIF2C2, MAN1C1 and DLGAP4 were negatively related to DNA methylation. Recently, the technology of using methylated DNA immunoprecipitation sequencing suggested that DNA methylation may play an important role in the epigenetic dysregulation of biological pathways in psoriasis. 28 miRNA-31 induced by NF-jB is one of the most dynamic miRNA identified in the skin of psoriatic patients and mouse models, whose aberrant rise in keratinocytes will promote their abnormal proliferation, increase acanthosis and inhibit the disease recovery in IL-23 mouse models. Study has confirmed that the protein phosphatase 6 (ppp6c) acting as a targeted molecular is a negative regulator that restricts the G1 to S phase progression. The rise of miR-31 directly inhibits ppp6c expression, thus enhancing keratinocyte proliferation. 42 Recently, the emergence of long non-coding RNA (lncRNA) has attracted our attention, defined as non-protein coding RNA transcripts longer than 200 nucleotides, are acting as key regulators of diverse cellular processes. Moreover, the expression levels of various lncRNA are closely related to epidermal differentiation and immunoregulation, 43 such as PRINS, which is elevated in non-lesional skin areas in patients with psoriasis while deceased in the lesion. GIP3, which is increased in the lesional skin areas, as its potential target gene, can reduce the sensitivity of keratinocytes to spontaneous apoptosis. 44 All these findings will benefit us in better understanding the molecular mechanism of psoriasis ( Fig. 2) .
MECHANISMS OF ENVIRONMENTAL RISK FACTORS' IMPACT ON PSORIASIS UV radiation exposure
Ultraviolet radiation from natural sunlight or artificial sources has been actually exploited for treating psoriasis in recent decades. The incidence of psoriasis may differ among various populations owing to regional disparity with distinct UV distribution. A casecontrol study explored absolute latitude suggesting that there was a wide variation in prevalence between 0% (in Samoa, average absolute latitude 13.35) and 3.3% (in Tanzania, average absolute latitude 6). 45 Moreover, sunscreen habits, altitude and ground reflection of UV light may also result in differences in average UV exposure. The mechanism of UV therapy mainly includes three aspects. First, more vitamin D can be produced by exposure to UV-B. Vitamin D is a hormone which plays a critical role in the treatment of psoriasis. Data shows that the optimal concentration of vitamin D (25[OH]D) in serum circulating level for maximum effect should be between 30 and 50 ng/mL (75-125 nmol/L). 35 . Therefore, if vitamin D is lower than 30 ng/mL, UV-B exposure will benefit patients a lot. 25(OH)D plays a vital role in the regulation of dendritic cells, the modulation of keratinocytes and the proliferation of T cells. 46, 47 Second, UV-B has pro-apoptotic effects leading to production of various pro-and anti-inflammatory cytokines. It simultaneously suppresses the differentiation of Th17 cells and inhibits IL-23/IL-17 expression. 48 In addition, UV exposure can reduce immune cells' migration to skin, and lower psoriasis-related antimicrobial peptides, particularly LL-37 and psoriasin which are visibly increased in psoriasis. 49 Studies showed that APC and autoreactive dermal T cells with intense stimulation were considered to be primary initiating factors contributing to the pathogenesis of this condition. 45 ,50 UV-B is an excellent therapeutic option for moderate psoriasis because of its high efficacy, relative safety and affordability. Weatherhead et al. 51 investigated whether UV-B has higher efficacy in clearing psoriatic lesions and inducing remission. They also pointed out that only 311-nm UV-B could contribute to fatal apoptosis in lesional epidermis, and the main apoptotic cells were keratinocytes. What is more, they provided a new insight into the use of keratinocyte apoptosis as a promising biomarker to further explore which wavelengths of UV-B were most effective in curing psoriasis. 
Medications
Studies have showed that many drugs, such as antiproliferative agents (imiquimod), antivirals and antidepressants (lithium), antihypertensives (beta-blockers), TNF-a, and many novel biologics including anticytokine therapies used in the treatment of psoriasis (anti-TNF antibodies), have all been clinically associated with initiation and exacerbation of psoriasis. 53 The most widely accepted hypothesis suggests there is an interaction between TNF-a and IFN-a. IFN-a is an important cytokine that controls natural immunity and is mainly produced from plasmacytoid dendritic cells through stimuli such as infection or trauma. IFN-a is also identified as a key element in the early phase of psoriatic induction. TNF-a negatively regulates IFN-a production. Therefore, anti-TNF-a therapy could increase IFN-a expression at the tissue level and induce psoriasis. 54 Vinter et al. 55 induced a psoriasis-like inflammatory skin condition through applying Aldara â (Aldara 5%; Meda, Solna, Sweden) cream containing 5% imiquimod, which may be because of its defective recruitment of adaptive immune system and the strong stimulation of IL-10 counter-regulation. Imiquimod is a Toll-like receptor 7/8 agonist used to treat genital warts and non-melanoma skin tumors. It can activate the type I IFN-signaling pathway and has been considered as one of the best investigated triggers of psoriasis. 56 Dalkilic et al. 57 conducted a research involving 514 patients treated with anti-TNF-a and matched healthy controls in Turkey. The incidence of anti-TNF-a-induced psoriasis was 1.16% (6/514 patients) which suggested that biological agents should be restricted to an appropriate application field and physicians should take full account of their indications. Sahuquillo-Torralba et al. 58 found that pembrolizumab, a new drug approved by the FDA for cancer immunotherapy, could worsen the symptoms of psoriasis. These drugs mainly aim at interfering with the individual's immune system, resulting in psoriasis induction. The mechanisms by which the drugs trigger psoriasis are complicated, so the clinical application of those drugs inevitably encounters some difficulties.
Smoking
Smoking or secondhand smoke exposure is a possible risk factor for psoriasis. However, controversial results are also observed. 59, 60 The exact impact of smoking on disease activity of psoriasis is not clearly known yet. Studies have showed that smoking can increase the activity of spondyloarthritis and rheumatoid arthritis, thus reducing quality of life. [61] [62] [63] Hojgaard et al. 64 conducted an observational research of 1388 psoriatic patients to study the correlation between smoking and treatment effect of TNF-a inhibitors. The result showed that heavy smoking could decrease the treatment effect of TNF-a-targeted drugs, and the impact seemed partially reversible. Naldi et al.
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directed an interesting comparative study and showed that smoking expedited the occurrence of psoriatic arthritis in patients without psoriasis, while it slowed down the recurrence of psoriatic arthritis in patients with psoriasis. The reasons why smoking is a possible risk factor of psoriasis are highly complex due to a variety of unknown toxins contained in cigarettes. However, one critical reason is the binding between nicotine and nicotinic acetylcholine receptors (nAChR) leading to disruptions of normal nervous system signaling. The nAChRmediated transduction pathway can regulate keratinocyte function. Also, many immune cells including T cells, B cells leukemic cell lines and thymocyte, have active nAChR and nicotine binding to these receptors interferes with immune cell signaling. 65 What is more, it is believed that smoking is positively related to an increased risk of psoriatic comorbidity including cardiovascular diseases. 66 
Alcohol intake
Even though the hypothesis that alcohol consumption is associated with the increased risk of psoriasis onset and worsening is not credible enough, studies showed that alcohol could directly and indirectly enhance the production of pro-inflammatory cytokines from many cell types, leading to persistent systemic inflammation and promoting lymphocyte proliferation. Moreover, alcohol and acetone could directly stimulate keratinocyte proliferation and increase the mRNA levels of genes characteristic of proliferating keratinocytes, such as a5 integrin, cyclin D1 and keratinocyte growth factor receptor. In addition, acetylcholine may also trigger psoriasis. 67 Qureshi et al. 31 suggested that there was an obviously positive correlation between heavy beer intake and risk of developing psoriasis among women, whereas another survey showed that alcohol intake may exacerbate psoriasis severity. 68 The relationship between psoriasis and alcohol intake is complicated, and different studies reached various conclusions. However, the consensus is that patients with moderate to severe psoriasis have a higher incidence and mortality of alcohol-associated diseases, including cardiovascular diseases and tristimania. 69 Brenaut et al. conducted a systematic published work review in 2013 using the Medline, Embase and Cochrane databases. He found four of five studies showing that alcohol was a risk factor for psoriasis. 70 The possible mechanism is that beer and some alcoholic beverages are made with wheat or other products containing gluten, so only those people who are sensitive to gluten frequently have symptoms. In conclusion, smoking and alcohol may induce the onset of psoriasis by various mechanisms, including immunological disorders such as keratinocyte hyperproliferation and overexpression of pro-inflammatory cytokines. 71 However, the exact mechanisms by which tobacco and alcohol induce psoriasis still require further investigation to verify the relation between tobacco and alcohol consumption and psoriasis.
Diet and obesity
Patients often wonder what they cannot eat and whether dietary changes can improve their symptoms or prevent recurrence. Of course, this refers to whether weight loss can contribute to their skin condition in this discussion. Association of psoriasis severity and high body mass index (BMI) score has been identified in several recent researches which suggest that bodyweight loss can improve Psoriasis Area and Severity Index score of the patients. 72 In addition, it is certain that healthy eating patterns would benefit psoriatic patients, including the use of oral vitamin B12, vitamin D, selenium and omega-3 fatty acids in fish oils. 73 73 found that fish oil seemed to be the most useful to improve the condition of patients in a randomized controlled trial. Recently, epidemiological and clinical studies 74 have provided a possible curative effect of a gluten-free diet for psoriasis. It was reported that a gluten-free diet seemed to be in certain psoriatic patients' favor according to some early evidence, but it also needed more trials in different populations. Obesity has been proved correlative with a pro-inflammatory state and numbers of study results have showed that being overweight could worsen psoriasis. Wolk et al. 75 conducted a case-control study composed of 373 psoriatic patients and matched healthy controls in 2009. They showed that obese individuals had a twofold increased risk to develop psoriasis in comparison with those of normal bodyweight. Furthermore, they found that each unit increase in BMI was associated with a 9% increase in the risk of psoriasis onset and a 7% increase in the risk of psoriasis severity. However, it is unknown whether psoriasis outcome was influenced by weight loss interventions, and still now none of any studies can expound the problem clearly. Several studies 76-78 have sought to establish the possible impact of diet change and weight loss on the therapeutic effect of psoriasis. They also showed a condition improvement in the process of psoriasis treatment and disease severity index that declined obviously after following a gluten-free diet for those anti-gliadin antibody (AGA)-positive patients. There is an agreement that overexpression levels of pro-inflammatory and anti-inflammatory cytokines is most important in the pathogenesis of psoriasis. Interestingly, obese individuals bear more chronic inflammation, which increases the risk for psoriasis onset. 79 A study conducted by Edson-Heredia et al. 80 explored which clinical factors in psoriasis correlated with the response to biologic therapy, and they found that BMI had the most intense response to biologics in the whole studies. Ustekinumab was mainly used for treating psoriasis and it was proved to be a promising biologic agent. Its phase III clinical trial showed that higher bodyweight was a potential predictor of worse response to it at the 28th week (P < 0.0001). 81 Based on the above studies, proper diet adjustment and healthy bodyweight may benefit psoriatic patients in the process of treatment but more clinical data is needed to confirm this conclusion.
Microbiota and psoriasis

Cutaneous microbiota and psoriasis
Skin and intestinal microbiota have been the focus of much attention in all fields recently, especially immunology. A summary of studies of microorganisms in psoriasis is displayed in Table 3 . There is a peaceful coexistence among bacteria, fungi and virus in a healthy body, which can develop an effective first-line barrier defense against pathogens and other environmental risk factors. The composition of the microbiome is specific to each individual. Usually, the microbes and their host interact with each other in a harmonious way. 82 However, disordered immune responses can cause inflammatory diseases, and the exact etiology remains unknown. Hajishengallis et al. 83 assumed that microbes could induce autoimmunity in those persons with a potential genetic susceptibility. Microecosystem disturbance induces infection when the host is in poor condition because of drug abuse, complications and undernutrition, together with other environmental factors such as diet, stress, and tobacco and alcohol intake. 84 Without the impact of environmental factors, the composition of the microbiome would remain relatively stable over a whole lifetime but change a little with aging. 85 Th17 cells have been identified as major constituents of psoriasis pathogenesis and many other autoimmune diseases. Cutaneous microbiota was revealed 100 years ago and accumulated evidences confirmed the relation between skin microorganisms and psoriatic lesions, such as streptococcal b-hemolytic group A throat infections linked to guttate psoriasis. 85 Drago et al. 86 also suggested that the type of microorganisms resides at different skin locations could influence the onset and the progression of cutaneous diseases. Studies showed that antibiotics targeting Gram-negative and Gram-positive bacteria could ameliorate psoriasiform dermatitis induced by imiquimod, and it inhibited the differentiation of T cells and the production of pro-inflammatory IL-17 and IL-22. 87 Importantly, T cells detected from psoriatic lesions react to streptococcal and staphylococcal peptidoglycan in an antigenspecific way. 88 Surprisingly, the deterioration of the skin inflammation is not related to the rise in IL-17-producing b + or cd + T cells. Instead, the severity of skin inflammation was mainly ascribed to prominent increase in skin T-cell-derived IL-22, especially T-cell receptor cd + IL-22 + cells. So, they suggested that IL-22-producing T cells, particularly cd + T cells, play the most vital role in the aggravation of skin inflammation. 87 Other microorganisms including Staphylococcus aureus, Malassezia and Candida are also involved in the pathogenesis of psoriasis. 89, 90 Staphylococcus and Streptococcus are commonly seen in all levels of skin. 90 Propionibacterium acnes are the main microorganisms located in a normal individual's skin but not in those influenced by psoriasis, 86, 91, 92 which may be a predictor of a disordered microbial system that induces the onset of psoriasis. A disordered micro-ecosystem probably plays a critical role in the pathogenesis of psoriasis or may be engaged in the disease exacerbation.
Intestinal microbiota and psoriasis
The intestinal microbiome plays a vital role in maintaining our intestinal mucosal barrier and normal immune function which exerts extra-intestinal regulation function at remote individual body sites. 93 There is a well-known correlation between
Crohn's disease (CD) and psoriasis. Patients with CD have a fivefold higher risk of developing psoriasis than those without CD. On the contrary, patients with psoriasis are more likely to suffer from CD. 94 More importantly, it has been reported that the innate immune system is active in psoriasis. Recently, studies have suggested that the mechanism of intestinal tract infection was similar to skin infection. Bacteroides fragilis can promote Treg differentiation via producing polysaccharide A and regulating the balance of Th1/Th2, 95, 96 while segmented filamentous bacteria direct Th17 cell differentiation, 97 and
Clostridium species promote Treg development. 98 Danese et al. proposed that a breakdown of immune tolerance affected by disordered microbiota of the intestinal tract may contribute to the onset of psoriasis. 99 However, the exact etiology of the activation has not been entirely clear. In fact, the presence of intestinal inflammation in psoriatic arthritis has been showed in multiple studies. [100] [101] [102] An obvious correlation is apparent between psoriasis and inflammatory bowel disease (IBD), and they have similarities in genetic factors and pathogenesis. 103, 104 Evidence showed that guttate psoriasis was commonly triggered by streptococcal infection, which even presented in the blood of psoriasis. 105 What is more, emotioninduced skin inflammation is related to dysbiosis in the intestinal microbiome. A hypothesis of the presence of the gutbrain-skin axis in normal individuals may be possible. 106 Studies have suggested that Streptococcus in the tonsils may contribute to the onset of chronic plaque psoriasis, 107 and bacteria in the intestinal tract would initiate and maintain psoriasis. 107 The microbiome may be the director, or a mediator at least, often involved in the common inflammatory pathways in autoimmune diseases. These explanations may also refer to other extra-intestinal clinical manifestations such as IBD and extracutaneous clinical manifestations such as psoriasis. 84 However, not all clinical data is consistent. This phenomenon may be concerned with susceptibility genes, which embody the interaction between environmental factors and genetics. The relationship between organism infection and psoriasis seems to be a vital and potentially promising field for future research.
Psychiatric factors
Psoriatic patients often feel nervous and great pressure because of their appearance. So, they are not willing to take daily physical activities or join in social activities, even fall into depression, the prevalence of which varies 10-62% according to different studies. In turn, depression can worsen psoriasis, forming a vicious circle. Stress in daily life is related to the new onset of psoriasis and will worsen the symptoms of psoriasis. 107 Park and Youn 109 also found that mental stress played a critical role in the occurrence, development and aggravation of psoriasis (P < 0.01). Psychological stress is known to impact psoriasis through immune system regulation and abnormal Tcell activation. 84 The most common psychiatric troubles related to dermatological conditions in general are depression, anxiety and suicidal thoughts. The biological links between psoriasis and depression are now well-established, and the psychiatric comorbidity is estimated to be approximately 30%. 110 Chamoun et al. 110 suggested that psoriasis has an important impact on the formation of a patient's personality in their childhood or adolescence. Conversely, personality will have an influence on the morbidity of psoriasis. Mart ın-Brufau et al.
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evaluated the relationship between emotional condition and skin lesions in a study of 823 psoriatic patients. Their data supported the association and also explained the association between the specific kind of emotions and psoriatic lesions. Therefore, it is essential to take care of the emotion of psoriatic patients. Sometimes, disease prevention is more important than the treatment of the disease in the clinic.
ENVIRONMENTAL FACTORS IN TREATMENT OF PSORIASIS
Treatment of psoriasis has been a long process, from the very first using coal tar, until now the classic treatment methods emerge, which involve methotrexate, cyclosporin, vitamin D derivatives, calcineurin inhibitors and newer biologic agents. However, most psoriatic patients are increasingly taking medicine to manage their symptoms clinically; some patients even have to take long-term drugs to maintain the condition while ignoring the important role of environmental factors in the development and prognosis of their diseases. Once their condition gets better, they continue to smoke, drink and eat extravagantly. What is worse, some of them are so ashamed of their bad appearance that they fall into depression, leading to recurrence. Therefore, psychological interventions including psychological counseling and relaxation therapy combined with related medications can offer benefits to most patients with psoriasis. Physicians should pay more attention to psychological comfort of their patients, encourage them to acquire confidence and teach them how to prevent psoriasis. Above all, prospective and case-control studies have certified that higher BMI, alcohol intake, smoking, drugs and infection are connected with a high risk of psoriasis. So, high BMI or AGApositive patients should adopt dietotherapy, which is eating more food containing rich vitamin D, losing weight and avoiding gluten in food, especially AGA-positive patients. Recently, studies have found the link between microbiota and psoriasis, so topical treatment takes anti-infection into consideration. More interestingly, a women's health study found that women who exercised regularly were less likely to have psoriasis than women who did not like to participate in regular physical activities. 112 Frankel et al. 113 also carried out a large cohort study to demonstrate that running and performing aerobic exercise or calisthenics could reduce risk of psoriasis, and the real effectiveness of physical activity would be impacted by the patients' mood. Exercise can relieve stress, reduce anxiety and tension, improve emotional well-being and help maintain an ideal weight. So, it may be a potentially promising treatment option for depression. 114 Moreover, outdoor sports encouraging optimal UV radiation exposure is an effective treatment for psoriasis plaque, which can replenish more vitamin D made in the skin regularly. Above all, the physician's final goal is to supervise patients maintaining a healthy, body free of infection, depression, obesity, alcohol and cigarettes. All the above environmental factors are interrelated and function together in the onset, development and recurrence of psoriasis. Therefore, the management of psoriasis should emphasize avoiding recurrence and improving the prognosis of psoriasis instead of only depending on drug therapy, especially for those who have high risk of family history or susceptibility genes.
CONCLUSION
Psoriasis is believed to be triggered by a combination of genetic, disordered immune system and environmental influences. Recently, numbers of studies showed that the environmental risk factors include UV, drugs, smoking and alcohol, infection and mental stress, all of which play a critical role in the pathogenesis of psoriasis. Currently, studies have showed that environmental risk factors affect the occurrence, progression and recurrence of psoriasis mainly via disturbing its genetics and immune system; as part of this process, the mechanisms of epigenetic modifications cannot be ignored. However, the exact evidence needs to be investigated more deeply and more risk factors wait to be discovered. Therefore, this review suggests that doctors should provide patients more recommendations on how to prevent the onset or recurrence of psoriasis as part of their daily lives.
